|
RAAS
Randomized Angiotensin receptor antagonist – ACE inhibitor Study
Ongoing trial
 |
Author(s) |
Pitt B, Chang P, Grossman W, Dunlay M, Timmermans PBMWM
|
 |
Title(s) |
Rationale, background, and design of the Randomized Angiotensin receptor antagonist - Angiotensin-converting enzyme inhibitor Study (RAAS)
|
|
Reference(s) |
Am J Cardiol 1996;78:1129-31
|
|
Disease |
Heart failure with left ventricular systolic dysfunction
|
|
Purpose |
To test the hypothesis that the addition of an angiotensin II type 1 receptor blocker (losartan) to an ACE inhibitor (enalapril) will provide better blockade of activation of the renin-angiotensin-aldosterone system in patients with heart failure and left ventricular systolic dysfunction, and to assess the safety of this therapy
|
|
Study design |
Randomised, double-blind, placebo-controlled, double-dummy
|
|
Follow-up |
6-48 weeks
|
|
Patients |
Aim 120 patients (3 treatment groups of 40 patients each) with heart failure and left ventricular systolic dysfunction
|
|
Treatment regimen |
Enalapril, 10 mg bid, plus either one of enalapril, 2.5-10 mg bid, losartan, 12.5-50 mg, or placebo
|
|
Results |
Not yet available
|
|
|
|
